Antibody Drug Conjugates
The global Antibody Drug Conjugates market was valued at 1565.46 Million USD in 2021 and will grow with a CAGR of 7.18% from 2021 to 2027, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact wwhich will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Antibody Drug Conjugates are highly effective biopharmaceutical medications designed as a targeted therapy for cancer treatment. The preparation process of ADC`s involves great difficulty, inspite of these hurdles recently approved ADC`s have proved their worth for treatment of cancer. Thus, there is a strong pipeline of ADC`s that promises revolutionary changes in area of targeted therapy for cancer treatment. This market is driven by elements such as continuous improvement in the clinical data and technological advancements in the field of drug development shelling out innovative drugs into the market.
By Market Verdors
F. Hoffman-La Roche
Novartis AG
Takeda Pharmaceutical
Pfizer
Seattle Genetics
Genentech
Immunogen
Progenics Pharmaceuticals
Bayer Healthcare Pharmaceuticals
By Types
Adcetris
Kadcyla
By Applications
Breast Cancer
Lymphoma
Key Indicators Analysed
Market Players & Competitor AnalysisThe report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market AnalysisThe report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market TrendsMarket key trends which include Increased Competition and Continuous Innovations.
Opportunities and DriversIdentifying the Growing Demands and New Technology
Porters Five Force AnalysisThe report provides with the state of competition in industry depending on five basic forcesthreat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements
Table of Content
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Antibody Drug Conjugates Revenue
1.4 Market Analysis by Type
1.4.1 Global Antibody Drug Conjugates Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 Adcetris
1.4.3 Kadcyla
1.5 Market by Application
1.5.1 Global Antibody Drug Conjugates Market Share by Application: 2022-2027
1.5.2 Breast Cancer
1.5.3 Lymphoma
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Antibody Drug Conjugates Market
1.8.1 Global Antibody Drug Conjugates Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Antibody Drug Conjugates Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Antibody Drug Conjugates Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Antibody Drug Conjugates Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Antibody Drug Conjugates Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Antibody Drug Conjugates Sales Volume Market Share by Region (2016-2021)
3.2 Global Antibody Drug Conjugates Sales Revenue Market Share by Region (2016-2021)
3.3 North America Antibody Drug Conjugates Sales Volume
3.3.1 North America Antibody Drug Conjugates Sales Volume Growth Rate (2016-2021)
3.3.2 North America Antibody Drug Conjugates Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Antibody Drug Conjugates Sales Volume
3.4.1 East Asia Antibody Drug Conjugates Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Antibody Drug Conjugates Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Antibody Drug Conjugates Sales Volume (2016-2021)
3.5.1 Europe Antibody Drug Conjugates Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Antibody Drug Conjugates Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Antibody Drug Conjugates Sales Volume (2016-2021)
3.6.1 South Asia Antibody Drug Conjugates Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Antibody Drug Conjugates Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Antibody Drug Conjugates Sales Volume (2016-2021)
3.7.1 Southeast Asia Antibody Drug Conjugates Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Antibody Drug Conjugates Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Antibody Drug Conjugates Sales Volume (2016-2021)
3.8.1 Middle East Antibody Drug Conjugates Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Antibody Drug Conjugates Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Antibody Drug Conjugates Sales Volume (2016-2021)
3.9.1 Africa Antibody Drug Conjugates Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Antibody Drug Conjugates Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Antibody Drug Conjugates Sales Volume (2016-2021)
3.10.1 Oceania Antibody Drug Conjugates Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Antibody Drug Conjugates Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Antibody Drug Conjugates Sales Volume (2016-2021)
3.11.1 South America Antibody Drug Conjugates Sales Volume Growth Rate (2016-2021)
3.11.2 South America Antibody Drug Conjugates Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Antibody Drug Conjugates Sales Volume (2016-2021)
3.12.1 Rest of the World Antibody Drug Conjugates Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Antibody Drug Conjugates Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Antibody Drug Conjugates Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Antibody Drug Conjugates Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Antibody Drug Conjugates Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Antibody Drug Conjugates Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Antibody Drug Conjugates Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Antibody Drug Conjugates Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Antibody Drug Conjugates Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Antibody Drug Conjugates Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Antibody Drug Conjugates Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Antibody Drug Conjugates Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Antibody Drug Conjugates Sales Volume Market Share by Type (2016-2021)
14.2 Global Antibody Drug Conjugates Sales Revenue Market Share by Type (2016-2021)
14.3 Global Antibody Drug Conjugates Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Antibody Drug Conjugates Consumption Volume by Application (2016-2021)
15.2 Global Antibody Drug Conjugates Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Antibody Drug Conjugates Business
16.1 F. Hoffman-La Roche
16.1.1 F. Hoffman-La Roche Company Profile
16.1.2 F. Hoffman-La Roche Antibody Drug Conjugates Product Specification
16.1.3 F. Hoffman-La Roche Antibody Drug Conjugates Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Novartis AG
16.2.1 Novartis AG Company Profile
16.2.2 Novartis AG Antibody Drug Conjugates Product Specification
16.2.3 Novartis AG Antibody Drug Conjugates Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 Takeda Pharmaceutical
16.3.1 Takeda Pharmaceutical Company Profile
16.3.2 Takeda Pharmaceutical Antibody Drug Conjugates Product Specification
16.3.3 Takeda Pharmaceutical Antibody Drug Conjugates Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Pfizer
16.4.1 Pfizer Company Profile
16.4.2 Pfizer Antibody Drug Conjugates Product Specification
16.4.3 Pfizer Antibody Drug Conjugates Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Seattle Genetics
16.5.1 Seattle Genetics Company Profile
16.5.2 Seattle Genetics Antibody Drug Conjugates Product Specification
16.5.3 Seattle Genetics Antibody Drug Conjugates Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Genentech
16.6.1 Genentech Company Profile
16.6.2 Genentech Antibody Drug Conjugates Product Specification
16.6.3 Genentech Antibody Drug Conjugates Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 Immunogen
16.7.1 Immunogen Company Profile
16.7.2 Immunogen Antibody Drug Conjugates Product Specification
16.7.3 Immunogen Antibody Drug Conjugates Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 Progenics Pharmaceuticals
16.8.1 Progenics Pharmaceuticals Company Profile
16.8.2 Progenics Pharmaceuticals Antibody Drug Conjugates Product Specification
16.8.3 Progenics Pharmaceuticals Antibody Drug Conjugates Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.9 Bayer Healthcare Pharmaceuticals
16.9.1 Bayer Healthcare Pharmaceuticals Company Profile
16.9.2 Bayer Healthcare Pharmaceuticals Antibody Drug Conjugates Product Specification
16.9.3 Bayer Healthcare Pharmaceuticals Antibody Drug Conjugates Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Antibody Drug Conjugates Manufacturing Cost Analysis
17.1 Antibody Drug Conjugates Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Antibody Drug Conjugates
17.4 Antibody Drug Conjugates Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Antibody Drug Conjugates Distributors List
18.3 Antibody Drug Conjugates Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Antibody Drug Conjugates (2022-2027)
20.2 Global Forecasted Revenue of Antibody Drug Conjugates (2022-2027)
20.3 Global Forecasted Price of Antibody Drug Conjugates (2016-2027)
20.4 Global Forecasted Production of Antibody Drug Conjugates by Region (2022-2027)
20.4.1 North America Antibody Drug Conjugates Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Antibody Drug Conjugates Production, Revenue Forecast (2022-2027)
20.4.3 Europe Antibody Drug Conjugates Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Antibody Drug Conjugates Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Antibody Drug Conjugates Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Antibody Drug Conjugates Production, Revenue Forecast (2022-2027)
20.4.7 Africa Antibody Drug Conjugates Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Antibody Drug Conjugates Production, Revenue Forecast (2022-2027)
20.4.9 South America Antibody Drug Conjugates Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Antibody Drug Conjugates Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Antibody Drug Conjugates by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Antibody Drug Conjugates by Country
21.2 East Asia Market Forecasted Consumption of Antibody Drug Conjugates by Country
21.3 Europe Market Forecasted Consumption of Antibody Drug Conjugates by Countriy
21.4 South Asia Forecasted Consumption of Antibody Drug Conjugates by Country
21.5 Southeast Asia Forecasted Consumption of Antibody Drug Conjugates by Country
21.6 Middle East Forecasted Consumption of Antibody Drug Conjugates by Country
21.7 Africa Forecasted Consumption of Antibody Drug Conjugates by Country
21.8 Oceania Forecasted Consumption of Antibody Drug Conjugates by Country
21.9 South America Forecasted Consumption of Antibody Drug Conjugates by Country
21.10 Rest of the world Forecasted Consumption of Antibody Drug Conjugates by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices